Non-carbapenemUTIβ-Lactam/β-lactamase inhibitorThis systematic review was conducted to compare the efficacy of non-carbapenem 尾-lactam/尾-lactamase inhibitors (BLBLIs) versus carbapenems for the treatment of urinary tract infections (UTIs) caused by extended-spectrum 尾-lactamase-producing ...
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated ... V Celeste,H Jose,A Nishaal - 《Drug Design Development & Therapy》 被引量: 9发表: 2016年 Ceftazidime-avibactam a novel cephalosporin/ be...
A non-beta-lactam antibiotic inhibitor for enterohemorrhagic Escherichia coli O104:H4Dynamic simulationβ-LactamaseE. coliO104: H4Non-β-lactam inhibitorThe overuse of antibiotics has caused an increased prevalence of drug-resistant bacteria. Bacterial resistance in E. coliis regulated via production ...
The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci, 8(ll):2330-2337, Nov 1999.Powers, R. A.; Blazquez, J.; Weston, G. S.; Morosini, M. I.; Baquero, F.; Shoichet, B. K. The complexed structure and antimicrobial ...
Shoichet, The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase, Protein Sci. 8 (1999) 2330^2337.Powers, R. A., Blazquez, J., Weston, G. S., Morosini, M. I., Baquero, F., and Shoichet, B. K. (1999) The complexed structure and...
beta-LactamaseE. coli O104: H4Non-beta-lactam inhibitorThe overuse of antibiotics has caused an increased prevalence of drug-resistant bacteria. Bacterial resistance in E. coli is regulated via production of beta-lactam-hydrolyzing beta-lactamases enzymes. Escherichia coli O104: H4 is a multi-...
beta-lactam-beta-lactamase inhibitors (BLIs) have previously demonstrated antimicrobial activity against Acinetobacter baumannii (AB). Colistin retains the highest susceptibility rate against A. baumannii, and has demonstrated synergy with other antimicrobials, including beta-lactam-BLIs. Therefore, we ...
beta-lactamase inhibitorenzymesstructure-based virtual screeningmolecular dockingantibioticsBackground: There is an urgent need to develop novel inhibitors against clinically widespread extended-spectrum beta-lactamases (ESBLs) to meet the challenges of the ever-evolving threat of antibiotic resistances. Most...